|
See related Myozyme powd for inj information |
|
|
|
Manufacturer |
Genzyme |
|
Distributor |
Hong Kong: DKSH |
|
Contents |
Alglucosidase alfa |
|
Indications |
Treatment for Pompe disease (GAA deficiency). |
|
Dosage |
20 mg/kg body wt IV every 2 wk. Infusion rate: Initially <1 mg/kg/hr, may be increased to 2 mg/kg/hr every 30 min until max 7 mg/kg/hr. |
|
Special Precautions |
General anaesth. Patients w/ infusion reactions. Acute underlying illness. Pregnancy & lactation. |
|
Adverse Drug Reactions |
Cardioresp failure, anaphylactic reactions, cardiac arrest, pneumonia, resp failure, resp distress, catheter-related infection, resp syncytial virus infection, gastroentiritis, fever, diarrhea, rash, vomiting, cough, otitis media, decreased oxygen saturation.
View ADR Monitoring Form |
|
Pregnancy Category (US FDA) |
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters). |
|
ATC Classification |
A16AB07 - alglucosidase alfa ; Belongs to the class of enzymes. Used in the treatment of alimentary tract and metabolism problems. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Myozyme powder for injection |
|
|
|
Manufacturer: |
Genzyme |
|
Distributor: |
Hong Kong: DKSH
|
|
|
|
